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Tomasz Zdrojewski4, Piotr Jankowski5
A b s t r a c t
Introduction: Familial hypercholesterolemia (FH) is a  severely underdiag-
nosed and undertreated genetic disorder. Little is known about regional 
variation in the prevalence of FH, and information for Central and Eastern 
Europe (CEE) is scarce. This paper assesses the prevalence of FH and related 
cardiovascular disease (CVD) risk factors in Poland.
Material and methods: We performed a  meta-analysis of six popula-
tion-based studies in Poland. The FH was assessed using the Dutch Lipids 
Clinics Network (DLCN) criteria. The categories “definite” (> 8 points) and 
“probable” (6–8 points) were combined into “potential FH”. Combined es-
timates of proportions across studies were pooled by meta-analysis with 
a random effects model.
Results: A  total of 37,889 persons aged 20–79 years were included in the 
analysis. The distribution of DLCN scores was skewed, and there were only 
7 cases of definite FH. Prevalence of potential FH was 404/100,000 people 
(95% CI = 277–531/100,000). Familial hypercholesterolemia was more prev-
alent in women than in men, and the prevalence was the highest in the age 
group 45–54 years in men and 55–64 years in women. After adjustment for 
age and sex, compared to participants with normal cholesterol, persons with 
potential FH had twice the prevalence of hypertension (p < 0.01); smoking 
was more prevalent by about 80% (p < 0.01) and hypertriglyceridemia was 
nine times more frequent (p < 0.001). There was no difference in the preva-
lence of low high-density lipoprotein (HDL)-cholesterol or diabetes.
Conclusions: We believe that our study might facilitate the planning of 
a strategy to manage the disease at a population level, i.e. to develop a na-
tional strategy for the detection, diagnosis, and treatment of FH.
Key words: familial hypercholesterolemia, Dutch Lipids Clinics Network 
criteria, risk factors, epidemiology, prevalence.
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Introduction
Familial hypercholesterolemia (FH) is an auto-
somal dominant condition characterized by the 
life-course elevated blood low-density lipoprotein 
(LDL)-cholesterol concentration. In most cases, 
mutations of the gene for the LDL receptor (LDLR) 
or for apoprotein B (ApoB) or for proprotein con-
vertase subtilisin/kexin type 9 (PCSK9) are found, 
but other forms of genetic mutations can also 
exist as very rare mutations of the LDLR adaptor 
protein 1 pathway. A vast majority of people with 
FH are heterozygotes. Heterozygous mutations of 
LDLR are present in about 90% of FH cases, while 
ApoB and PCSK9 were found in 5% and 1%, re-
spectively [1–3]. Familial hypercholesterolemia 
has been well recognized for over 50 years, but it 
has gained attention recently for several import-
ant reasons. First, it is related to early atheroscle-
rosis and premature coronary heart disease (CHD) 
and people with heterozygous FH are automatical-
ly considered as high-risk patients [4, 5]. Second, 
in many countries, the condition remains severe-
ly underdiagnosed and undertreated. Out of 22 
countries, in more than half the estimates of the 
proportion of individuals diagnosed with FH were 
not higher than 1% of all cases, and only in five 
countries did the proportion exceed 5%, reaching 
the absolutely exceptional maximum of 71% in 
the Netherlands [3]. Only about half of FH patients 
were receiving appropriate therapy [4, 6]. Further-
more, FH patients were more likely to smoke and 
to have a high concentration of blood triglycerides 
and lower chance of having blood pressure within 
the recommended limits [6]. Statins are consid-
ered to be the first-line therapy for patients with 
FH [7–9], but low-potency statins or moderate 
doses of higher potency statins are not effective 
enough. In consequence, higher doses of high-po-
tency statins are often needed to reach the goal 
of lowering LDL-C levels by 50% at least. Com-
bined treatment with ezetimibe, ER niacin, bile 
acid binding agents, or anti-PCSK9 antibodies is 
also postulated [10–12]. The problem of statin in-
tolerance is of particular importance as it affects 
10–15% of patients treated with statins in gener-
al, with some complications having been reported 
more with the use of synthetic, potent, and more 
lipophilic statins [13].
All this suggests that FH requires a specific de-
tection and treatment strategy that is firmly based 
on epidemiological evidence. It used to be gener-
ally believed that homozygous FH occurs in about 
1/100,000 people, and heterozygous FH in about 
1/500. However, these numbers were questioned 
because they were derived mainly from old clinical 
data. More recent studies indicated that the preva-
lence may reach 1/200 [3]. Data on prevalence of FH 
are not available for most countries because there 
is a  lack of national registers or screening strate-
gies in action. Furthermore, uniform criteria for the 
diagnosis of FH are not agreed, and there are three 
sets of criteria at least in broader use depending on 
the region of the world [2]. Genetic testing would 
be particularly beneficial to confirm the diagnosis 
in every individual case, but genetic screening was 
not found to be a cost-effective tool [14, 15].
The spectrum of FH mutations in Europe varies 
by country [2]. It is likely that there is also regional 
variation in the prevalence of FH in general. In-
formation for Eastern Europe is scarce. Even the 
flagship report on FH of the European Atheroscle-
rosis Society does not provide an estimate for di-
agnosed FH for a single Central or East European 
(CEE) country [3]. The findings in patients after 
hospitalization due to CHD indicate that the prev-
alence of FH seems to be high in CEE countries 
including Poland, in which 11.4% of patients were 
found to have definite or probable FH [6]. In Po-
land, several large population-based studies have 
been conducted, but the problem of FH was not 
addressed in any of them, as each of these stud-
ies had too low statistical power to deliver a more 
precise estimate.
The goal of this study was to assess the prev-
alence of FH and related cardiovascular disease 
(CVD) risk factors by a meta-analysis of the results 
of six large, population-based, observational stud-
ies carried out in Poland, using available data on 
phenotype of FH.
Material and methods
We used data from six population studies, car-
ried out in Poland in well-defined populations, in 
which at least 2,000 participants were examined. 
Detailed descriptions of the methods used in par-
ticular studies have been published elsewhere 
[16–23]. The list of populations studied and the 
information on recruitment and participation are 
presented in Table I.
For the present analysis, FH was assessed us-
ing the Dutch Lipids Clinics Network (DLCN) cri-
teria for diagnosis of heterozygous FH in adults 
[3, 24]. Participants were classified as follows: 
“definite FH” if they scored > 8 points, “probable 
FH” if they scored 6–8 points, and “possible FH” 
if they scored 3–5 points. In addition, categories 
“definite FH” and “probable FH” were combined 
into “potential FH.” The category “normal blood 
cholesterol” was defined as having total choles-
terol (TC) < 5 mmol/l and LDL-C < 3 mmol/l and 
not being on blood lipid-lowering treatment. In 
all studies, data on tendon xanthomas and arcus 
cornealis in participants or their families as well 
as data on first-degree relatives and children with 
LDL-C >  95th percentile by age and gender were 
not available. Also, no molecular genetic testing 
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was available, so the final classification was based 
on phenotype characteristics, i.e. blood LDL-cho-
lesterol and family or personal history of CHD and 
other acute atherosclerosis manifestations. The 
methods of blood processing and lipid determina-
tion are presented in Table II. In all studies, the 
information on family and personal history was 
collected by interview according to the question-
naire. All the available and relevant information on 
personal and family history of early CHD, stroke, 
and peripheral arterial disease (PAR) was used. 
Table III presents the information obtained to be 
used in the DLCN classification of FH.
Statistical analysis
In the first stage, calculations in each of the 
studies were conducted separately. Proportions 
in persons with FH and in persons with normal 
blood cholesterol were standardized directly to 
the sex-specific age distribution of the Polish pop-
ulation at the end of 2013. Then, combined esti-
mates of proportions across studies were pooled 
by meta-analysis technique. In the presence of 
heterogeneity within and between studies, ran-
dom effects methodology was chosen to obtain 
pooled prevalence [25]. The prevalence of FH by 
sex and age strata was obtained by much the 
same procedure except for the two extreme age 
groups (20–34 years, 65 years and over), in which 
fixed effect meta-analysis was applied. A  similar 
two-step approach was performed to determine 
the association between FH and CVD risk factors. 
First, a set of multiple regressions was carried out 
with risk factors as dependent variables and the 
FH vs. healthy group as the independent variable, 
adjusted for age and sex. The second step was to 
implement random effects model meta-analysis 
to calculate the combined measure of associa-
tion across the studies. The statistical calculations 
were performed with IBM SPSS Statistics  22 for 
Windows except the meta-analysis procedure. 
The R Metafor package [26] was used to pool esti-
mates across the studies p < 0.05 was considered 
statistically significant.
Results
Out of 39,768 participants examined in six 
studies, 37,889 individuals (47.8% men) were in-
cluded in the present meta-analysis. About 1,885 
(4.7%) participants were excluded, mainly be-
cause of missing LDL-C (1,343 persons) or the age 
being outside the range specific for each study at 
the date of examination (542 persons). The de-
tailed recruitment and participation numbers by 
study are given in Table I.
Severe hypercholesterolemia was not frequently 
found in the pooled sample included in the anal-
ysis. Very high LDL-cholesterol (≥ 6.5 mmol/l) was 
found only in 4.34‰ (95% CI: 3.19–5.48‰) and 
LDL-C  ≥  5  mmol/l was found in 5.79% (95% CI: 
4.52–7.05%) of all participants. The distribution of 
the DLCN scores was skewed, and about half of all 
participants had a  DLCN score of zero (Figure 1). 
In all 37,889 individuals studied, there were only 
7 cases of DLCN score > 8 points. Potential FH, i.e. 
definite and probable FH combined (score ≥ 6 points), 
was more prevalent. The average prevalence was 
404/100,000 people (95% CI: 277–531/100,000). 
However, the estimate of the average prevalence 
varied by study, with the minimum of 231/100,000 
and maximum of 548/100,000 (Table IV).
In Table V, the prevalence of potential and pos-
sible FH is presented by sex and by age group. Fa-
Figure 1. Distribution of Dutch Lipid Consensus 
Network (DLCN) score
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Table IV. Prevalence of potential (definite and probable combined) and possible familial hypercholesterolemia (FH) 
according to the Dutch Lipids Clinics Network (DLCN) criteria
Study name Potential FH Possible FH
‰ 95% CI % 95% CI
POL-MONICA Krakow 4.46 2.64–6.28 12.1 11.2–13.0
POL-MONICA Warszawa 5.01 3.13–6.90 13.5 12.6–14.5
WOBASZ 2.46 1.63–3.28 8.1 7.6–8.5
Pilot HAPIEE 5.38 2.21–8.56 12.9 11.4–14.3
HAPIEE 5.48 3.96–6.99 12.2 11.5–12.9
NATPOL 2011 2.31 0.29–4.34 5.9 4.9–6.9
Total 4.04 2.77–5.31 10.4 8.9–12.7
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milial hypercholesterolemia was more prevalent in 
women than in men, and the prevalence was the 
highest in the age group 45–54 years in men and 
55–64 years in women. At age 65 years and old-
er in men, the prevalence of FH was almost three 
times lower than the peak, and at age 65 years and 
older in women it was twice as low as the peak.
In Table VI, the characteristics of participants 
with potential and possible FH are compared 
with persons with normal blood cholesterol, i.e. 
TC < 5 mmol/l and LDL-C < 3 mmol/l. Persons with 
FH were older and included a higher proportion of 
women. By definition, positive history of CHD and 
other acute manifestations of atherosclerosis were 
more frequent in participants with FH. Still, about 
10% of participants with normal blood cholesterol 
had a history of stroke or acute or chronic CHD.
Participants with potential and with possible 
FH had higher exposure to some other risk fac-
tors. After adjustment for age and sex, compared 
to participants with normal cholesterol, persons 
with potential FH had twice as high prevalence 
of hypertension; smoking was more prevalent by 
about 80% and hypertriglyceridemia nine times 
more frequent. The prevalence of these risk fac-
tors was also higher in participants with possi-
ble FH; in particular, the prevalence of hypertri-
glyceridemia was four times higher compared to 
participants with normal blood cholesterol. Also, 
in participants with possible FH, higher preva-
lence of obesity was found. The prevalence of low 
HDL-cholesterol and diabetes was similar in par-
ticipants with FH and in participants with normal 
blood cholesterol (Table VII).
Discussion
We found that the prevalence of FH in Po-
land was between 277 and 531/100,000 people. 
The average estimate was 404/100,000, which 
equates to approximately 1/250 people.
To our best knowledge, this is the first estimate 
of the prevalence of FH in Poland, which is based 
on the results of larger studies carried out in 
well-defined populations. Furthermore, the stud-
ies included in the present meta-analysis used 
the standardized methods of observations, and 
in some cases, the methods were standardized 
across these studies to obtain comparable results. 
For example, the POL-MONICA Krakow and War-
saw studies used the same questionnaires and 
blood collection procedures, and laboratory proce-
dures were subjected to the same external quality 
control programs carried out by the CDC in Atlanta 
(USA) and by the MONICA Project Lipid Reference 
Center [16–18]. The WOBASZ Study used ques-
tionnaires largely based on POL-MONICA expe-
riences, and biochemical analyses were carried 
out in the same laboratory as in POL-MONICA 
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Table VI. Descriptive statistics for participants with potential (definite and probable combined) and possible fa-
milial hypercholesterolemia (FH) according to the Dutch Lipids Clinics Network (DLCN) criteria and for participants 
with normal blood cholesterol (TC < 5 mmol/l and LDL-C < 3 mmol/l)
Parameter
 
Potential FH  Possible FH  Normal blood lipids
Mean 
or %
95% CI Mean 
or %
95% CI Mean 
or %
95% CI
Mean age [years] 53.8 52.8–54.8 53.4 51.7–55.1 46.2 39.7–52.7
Men (%) 27.3 20.3–34.4 39.6 36.3–43.0 49.3 46.1–52.5
Mean BMI [kg/m2] 27.8 27.0–28.5 28.1 28.0–28.3 26.1 25.2–27.1
Current smokers (%) 41.3 33.5–49.1 34.5 28.2–40.9 36.0 31.1–40.9
Diabetes (%) 1.8 < 0.1–3.9 8.1 4.7–11.6 5.6 1.7–9.5
Hypertension (%) 68.6 60.9–76.3 62.9 61.3–64.4 41.1 30.4–51.9
History of CVD (%) 70.1 56.9–83.2 48.9 39.3–58.5 12.1 7.4–16.8
History of MI (%) 32.1 15.0–49.2 16.7 9.9–23.4 3.2 1.7–4.7
History of CABG or PCI (%) 6.5 < 0.1–15.4 3.2 1.8–4.7 0.6 0.1–1.0
History of AP (%) 49.3 29.3–69.3 35.0 23.6–46.4 8.6 4.6–12.5
History of brain stroke (%) 3.2 < 0.1–6.6 2.9 2.3–3.4 1.3 0.9–1.7
History of PAR (%) 2.5 < 0.1–5.8 4.5 2.3 –6.7 1.2 0.7–1.6
CVD and diabetes (%) 1.8 < 0.1–4.0 4.9 2.8–7.0 1.5 0.5–2.5
Lipid-lowering treatment (%) 14.1 3.6–24.6 16.9 8.6–25.2 – –
Mean TC [mmol/l] 8.7 8.2–9.2 6.8 6.6–7.0 4.3 4.3–4.4
Mean HDL-C [mmol/l] 1.4 1.4–1.5 1.4 1.4–1.4 1.4 1.4–1.49
Mean LDL-C [mmol/l] 6.4 6.0–6.9 4.6 4.4–4.8 2.4 2.3–2.4
TG (median, min–max) [mmol/l] 1.9 0.4–4.4 1.6 0.3–4.7 1.0 0.2–4.5
BMI – body mass index, CVD – cardiovascular disease, AP – angina pectoris, HA – heart attack, MI – myocardial infarction, 
PCI – percutaneous intervention, CABG – coronary artery bypass grafting, PAR – peripheral artery disease, TC – total cholesterol, HDL-C – high-
density lipoprotein cholesterol, LDL – low-density lipoprotein cholesterol, TG – triglycerides.
Table VII. Relation between familial hypercholesterolemia (FH) and prevalence of other cardiovascular disease 
(CVD) risk factors (reference group = participants with TC < 5 mmol/l and LDL < 3 mmol/l and not on blood lipid 
lowering treatment)
Parameter  Potential FH Possible FH
OR* 95% CI P-value OR* 95% CI P-value
BMI ≥ 30 kg/m2 1.16 0.80–1.68 0.44 1.25 1.10–1.41 0.0006
Smoking 1.75 1.23–2.48 0.002 1.27 1.16–1.39 < 0.0001
Diabetes 2.26 0.85–6.00 0.10 1.17 0.91–1.50 0.21
Hypertension 2.02 1.95–3.43 0.009 1.76 1.57–1.97 < 0.0001
Low HDL-C 1.66 0.84–3.27 0.14 1.31 1.08–1.60 0.006
TG > 1.7 mmol/l 9.05 6.10–13.44 < 0.0001 4.37 3.71–5.14 < 0.0001
BMI – body mass index, TC – total cholesterol, HDL-C – high-density lipoprotein cholesterol, LDL – low-density lipoprotein cholesterol, 
TG – triglycerides, *Adjusted for age and sex.
Warsaw. The methods in HAPIEE Krakow and the 
Pilot HAPIEE study were the same, and biochem-
ical analyses were done in a laboratory that par-
ticipated in the POL-MONICA Krakow study. Also, 
the strength of the analysis is that we were able 
to include data from two studies in which samples 
studied were selected from the total Polish popu-
lation (WOBASZ and NATPOL 2011).
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There are, however, certain limitations in the 
interpretation of the results. The first is that none 
of the studies included in the meta-analysis was 
designed to assess FH according to the DLCN or 
any other standard set of diagnostic criteria. The 
information on phenotype and family history in 
particular varied between the studies. This could 
bias the final results, resulting in decreased num-
bers of people classified with definite or probable 
FH. The samples studied differed in age. Including 
the age group below 35 years could result in a de-
crease in the number of detected cases, as in het-
erozygous FH the onset of CHD frequently appears 
after the age of 35 years. On the other hand, in the 
older age group, the proportion of persons with FH 
was smaller because of lower life expectancy and 
higher frequency of the use of blood lipid-low-
ering agents. Indeed, in studies which involved 
samples with a broader age span (WOBASZ and 
NATPOL 2011), the rates of FH were lower. In par-
ticipants aged 60–79 years (NATPOL 2011 study), 
the proportion of people taking statins was three 
times higher than the average for the total sam-
ple [22]. Blood lipid-lowering treatment could also 
lower the rates of FH in general. This would not 
be a problem of the early studies as treatment for 
hypercholesterolemia was infrequent, even mar-
ginal. The advantage of using data from the older 
studies might be that the bias due to the lipid-low-
ering treatment would be smaller than in more 
current observations. Indeed, in the later studies, 
the proportions of treated people were higher 
than in the old studies, but treatment of hyper-
cholesterolemia was still not a standard practice. 
In the WOBASZ study (a representative sample for 
Poland), only 12% of people with hypercholester-
olemia received treatment, and out of them, the 
treatment goals were reached only in every fifth 
person [19]. In the most recent study (NATPOL 
2011), the proportion was similar [22]. It is likely 
that the effect of blood lipid-lowering treatment 
on our results was rather small. In the Finnish pop-
ulation study, mutation carriers who were treated 
with lipid-lowering medication had similar LDL-C 
to carriers who were not treated [27]. Also, lack 
of information on genetic mutations might be of 
smaller importance, as in the untreated, predom-
inantly middle-age population, cases of FH with 
normal blood LDL-C or only slightly over the nor-
mal values should be very rare.
Like in the other studies, there were differenc-
es in FH prevalence according to age [4, 6, 28, 
29], which could be explained by the impact of 
increasing age and weight on LDL-C when using 
DLCN criteria. Higher prevalence in women was 
also found in some studies [4, 6, 30] but not in 
all [28–30]. Besides the effects of age and weight, 
these observations can also be explained by the 
differences in life expectancy between men and 
women. Familial hypercholesterolemia was found 
to be related to higher exposure to other CVD risk 
factors. Our study design does not allow for con-
clusions on causality, but these results call for in-
tensifying the intervention in clinical practice. 
Direct comparisons between our findings and 
the results of other studies are difficult due to 
the differences in the design and methods used. 
Most evidence on the prevalence of FH is based 
on data from registers whose coverage is difficult 
to control [31]. In a few studies, the studied sam-
ples were representative of a  larger population, 
but they were rarely large enough to provide re-
liable estimates of the prevalence. Our estimate 
is slightly lower compared to the results of the 
well-designed and frequently cited Danish study 
and close to the estimate of the European Athero-
sclerosis Society [3, 4]. Also, our results are close 
to the results obtained using similar methods 
from the US NHANES 2001–2012 datasets (nearly 
60,000 persons) and similar to results of the stud-
ies from Australia and China (18,000 and 10,000 
persons respectively) [28–30]. Our estimate of the 
prevalence is twice as high compared to the Finn-
ish study (over 28,000 persons), which was based 
on finding genetic mutations which are present in 
about 70% of all FH cases in Finland [27]. 
Observations from the younger groups of the 
Polish population, i.e. below the age of 20 years, 
would add complementary information leading 
to better assessment of FH in the Polish popula-
tion. However, it is unlikely that it will be accom-
plished in the near future, as cholesterol screening 
is not recommended for people below the age of 
18 years. The postulated tool for the detection of 
FH is cascade screening. This is based on detailed 
examinations of the first- and second-degree rel-
atives of the probands (index cases). The latter 
might emerge from either by-chance examination 
or from the population screening, which would 
provide information on blood cholesterol, prema-
ture CHD, and cardiac deaths in family members 
or tendon xanthomas in the proband or his/her 
family member [3, 5, 8, 32].
We believe that our study allows for a  bet-
ter understanding of how many cases of FH can 
emerge from the population cholesterol screening 
facilitating the planning of a strategy to manage 
the disease at a  population level. We hope that 
our results will draw the attention of health man-
agers and clinicians, particularly primary care phy-
sicians involved in population cholesterol screen-
ing in the group of people with potential FH. In 
Poland, a  country with 38 million residents, the 
size of this group is about 150,000 ±50,000 adult 
people. These people require special diagnostics 
which would involve not only themselves but also 
all of their first- and second-degree relatives and 
which would include genetic testing and other 
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more sophisticated biochemical diagnostics. Fur-
thermore, it could be expected that many of them 
would require intensive treatment with high dos-
es of highly potent statins alone or in combination 
with other lipid-lowering agents including new 
generations of efficacious drugs [24, 33]. All these 
points need to be addressed urgently, to develop 
a  national strategy for the detection, diagnosis, 
and treatment of FH.
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